UCB'S CIMZIA EFFECTIVE AND WELL-TOLERATED

Belgian pharmaceutical group UCB has reported that Phase III study results for its Cimzia treatment for Crohn's disease show the drug is effective at decreasing or controlling the symptoms of the condition.

A regulatory submission for the treatment of Crohn's disease is scheduled to be filed for Cimzia in both the US and Europe during the first quarter of 2006.